A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia

Launched by SHANDONG UNIVERSITY · May 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of a specific antibiotic called piperacillin-tazobactam to treat pneumonia in older patients, specifically those aged 65 and older. The trial aims to compare two different ways of giving the antibiotic: one method involves an infusion every 6 hours for 4 hours, while the other method is every 8 hours for 3 hours. Researchers want to find out which method is more effective and safer for elderly patients with pneumonia.

To be eligible for this study, participants must be over 65 years old, have a clinical diagnosis of pneumonia, and be receiving treatment with intravenous piperacillin-tazobactam. However, individuals with a history of allergy to certain antibiotics, those undergoing severe medical treatments like continuous renal replacement therapy, or those with serious health issues like cancer will not be included. If you or a loved one qualifies, you can expect to be closely monitored during the study to help improve how pneumonia is treated in older adults.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age must be greater than 65 years Clinical diagnosis of Pneumonia Receiving intravenous piperacillin-tazobactam treatment
• Exclusion Criteria:
• • History of allergy to β-lactam antibiotics Continuous renal replacement therapy, severe organ dysfunction Malignant tumor disease